Trial Profile
A Phase IIIb, open label trial, to assess the safety, tolerability and efficacy of dihydroartemisinin/piperaquine (EurartesimÂ) in Indian children and adolescent patients with acute uncomplicated Plasmodium falciparum malaria
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 04 Jul 2019
Price :
$35
*
At a glance
- Drugs Dihydroartemisinin/piperaquine (Primary)
- Indications Falciparum malaria
- Focus Adverse reactions
- 03 Jan 2018 New trial record